

World-Class Mechanical Thrombectomy

Spiroflex Technology with Twice the Power

Our most powerful coronary AngioJet catheter with 0.014" guide wire compatiblity

Spiroflex® VG
ANGIOJET
thrombectomy set

AngioJet® Spiroflex® VG Thrombectomy Catheter

Rapid Exchange with Exceptional Flexibility and Power

Powerful Thrombectomy

The SpiroflexVG catheter offers twice* the clot removal power compared to our market-leading AngioJet 4F RX catheters. Specially engineered tip design takes powerful advantage of our patented Cross-Stream® technology to capture and remove more organized, more mature thrombus, and remove larger thrombus burden.

With over 600,000 cases performed, the AngioJet Thrombectomy System is the proven leader in the safe and effective removal of thrombus.

SpiroflexVG Technology Shaft

- Flexibility of the polymer-clad, spiral shaft increases toward the distal end to accommodate tight bends while retaining excellent pushability at the proximal end
- Distal shaft has hydrophilic coating to reduce drag and ensure smooth delivery
- Catheter diameter is compatible with 7F guides which allows the SpiroflexVG catheter to effectively treat vessels and saphenous vein grafts ≥ 3mm

Unique Tip Design

- Long taper tip provides excellent crossing profile
- Soft tip material conforms and tracks through tight vessels
- Bright orange tip for easier guidewire loading
- 25cm guidewire lumen for faster loading and unloading

*In bench tests using simulated clot material.



Patented Cross-Stream® technology provides fast and effective 360° thrombus removal.

Attached Clot Removal*



Catheter Specifications

System Compatibility	AngioJet Ultra
Vessel Diameter	≥ 3mm
Working Length	135cm
Shaft Diameter	5F
Guidewire Compatibility	0.014"
Guide Compatibility	7F > 0.076"
Sheath Compatibility	6F
Flow Rate	60 mL/min

Ordering Information

AngioJet Ultra SpiroflexVG Thrombectomy Set	106608-TAB

Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific *Information for Use* for your country.

Caution: Federal (US) law restricts this device to sale by or on the order of a physician.

AngioJet® Thrombectomy Systems

Indications/Contraindications

AngioJet and AngioJet Ultra peripheral indications include: breaking up and removing thrombus from infra-inguinal peripheral arteries, upper and lower extremity peripheral arteries, upper extremity peripheral veins, ileofemoral and lower extremity veins, A-V access conduits, and for use with the AngioJet Ultra Power Pulse Kit for the control and selective infusion of physician specified fluids, including thrombolytic agents, into the peripheral vascular system. Coronary indications include: removing thrombus in the treatment of patients with symptomatic coronary artery or saphenous vein graft lesions prior to balloon angioplasty or stent placement. Do not use in patients: who are contraindicated for intracoronary or endovascular procedures, who cannot tolerate contrast media, and in whom the lesion cannot be accessed with the wire guide.

Warnings and Precautions

The system has not been evaluated for treatment of pulmonary embolism or for use in the carotid or cerebral vasculature. Some AngioJet devices have not been evaluated for use in coronary vasculature. Operation of the catheter may cause embolization of some thrombus and/or thrombotic particulate debris. Cardiac arrhythmias may occur and cardiac rhythm should be monitored during catheter use and appropriate management employed, if needed. Systemic heparinization is advisable to avoid pericatheterization thrombus and acute rethrombosis. Operation of the system causes transient hemolysis. Large thrombus burdens may result in significant hemoglobinemia which should be monitored. Consider hydration, as appropriate. Before coronary AngioJet treatment, verify the presence of thrombus because routine use of AngioJet in every STEMI patient, without proper selection for thrombus, has been associated with increased mortality risk. Do not use the system in the coronary vasculature without placing a temporary pacing catheter to support the patient through hemodynamically significant arrhythmias which may occur.

Potential Adverse Events

Potential adverse events (in alphabetical order) which may be associated with use of the system are similar to those associated with other interventional procedures and include but are not limited to the following: abrupt closure of treated vessel, acute myocardial infarction, acute renal failure, arrhythmias (including VF and VT), bleeding from access site, death, dissection, embolization (proximal or distal), emergent CABG, hematoma, hemolysis, hemorrhage requiring transfusion, hypotension/hypertension, infection at access site, myocardial ischemia, pain, pancreatitis, perforation, pseudoaneurysm, reactions to contrast medium, stroke/CVA, thrombosis/occlusion, total occlusion of treated vessel, vascular aneurysm, vascular spasm, vessel wall or valve damage.

Refer to product labeling for device-specific indications, contraindications, warnings/precautions, and adverse events. Rx only. – COM January 2011

Bayer HealthCare

Manufacturer:

MEDRAD, INC.
One Medrad Drive
Indianola, PA 15051-0780 USA
Ph: +1 (412) 767-2400
Other: +1 (800) 633-7231
Fax: +1 (412) 767-4120
www.interventional.bayer.com

European Authorized Representative:

MEDRAD Europe B.V.
P.O. Box 205
6190 AE Beek
The Netherlands
Ph: +31 (0) 43-3585600

CE 0086

4036-TAB 2/2013

G.RI.03.2013.0047